NCT06234046View on ClinicalTrials.gov

Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 28, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

December 15, 2023

Conditions
Spontaneous Bacterial Peritonitis
Interventions
DRUG

Rifaximin 550Mg Tab

group (1) received Rifaximin as 550 mg twice daily dosage for six months.

DRUG

Ciprofloxacin 750 MG

group (2) received Ciprofloxacin 750 mg tab mg once weekly dosage for six months.

DIAGNOSTIC_TEST

ascitic fluid sample

aspiration of ascitic fluid sample and analysis for differential cell count

Trial Locations (1)

3753450

Mostafa Elfors, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06234046 - Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin | Biotech Hunter | Biotech Hunter